Oct 16, 2024: Unlock exclusive Fall discounted rates and elevate your research with B.R.I.D.G.E. TO DATA®
Seize the opportunity with our Fall Special and maximize your year-end budget!
Sep 26, 2024: National Registry of Rare Kidney Diseases (RaDaR)
Established in 2010, the National Registry of Rare Kidney Diseases (RaDaR) is an initiative by the UK Kidney Association. Its purpose is to gather longitudinal data on patients diagnosed with specific rare kidney diseases. With 33,000 patients enrolled from 109 sites throughout the UK, RaDaR stands as the largest rare kidney disease registry globally.
Sep 25, 2024: Our latest Multiple Sclerosis Registry is from Denmark
The Danish Multiple Sclerosis Registry is one of the oldest and largest MS registries globally, housing nationwide prospective data on all Danish residents diagnosed with MS from 1948 to the present. The registry undergoes a new build approximately every month, during which data are extracted, checked, and cleaned.
Sep 18, 2024: Creating Collections - Tutorial update
We are excited to announce the recent enhancements and upgrades in our tutorial - How to Create Collections on B.R.I.D.G.E. TO DATA®. This updated video demonstrates how to narrow down search results, save collections for future use, and leverage new features for even better profile comparisons.
National Registry of Rare Kidney Diseases (RaDaR) (United Kingdom)
Database Contact Data
Professor Danny Gale
Director
RaDaR Team
UNITED KINGDOM
Email: d.gale@ucl.ac.uk
Alternate Contact
Dr. Zoe Plummer
Senior Project Manager
RaDaR Team
UNITED KINGDOM
Email: zoe.plummer@ukkidney.org
References of Studies Using/Describing Database
1. Pitcher D, Braddon F, Hendry B, Mercer A, Osmaston K, Saleem MA, Steenkamp R, Wong K, Turner AN, Wang K, Gale DP, Barratt J. Long-Term Outcomes in IgA Nephropathy. Clin J Am Soc Nephrol. 2023 Jun 1;18(6):727-738.
2. Wong K, Pitcher D, Braddon F, Downward L, Steenkamp R, Masoud S, Annear N, Barratt J, Bingham C, Coward RJ, Chrysochou T. Description and Cross-Sectional Analyses of 25,880 Adults and Children in the UK National Registry of Rare Kidney Diseases Cohort. Kidney International Reports. 2024 May 9; 2067–2083.
3. Wong K, Pitcher D, Braddon F, Downward L, Steenkamp R, Annear N, Barratt J, Bingham C, Chrysochou C, Coward RJ, Game D, Griffin S, Hall M, Johnson S, Kanigicherla D, Karet Frankl F, Kavanagh D, Kerecuk L, Maher ER, Moochhala S, Pinney J, Sayer JA, Simms R, Sinha S, Srivastava S, Tam FWK, Turner AN, Walsh SB, Waters A, Wilson P, Wong E, Taylor CM, Nitsch D, Saleem M, Bockenhauer D, Bramham K, Gale DP; RaDaR consortium. Effects of rare kidney diseases on kidney failure: a longitudinal analysis of the UK National Registry of Rare Kidney Diseases (RaDaR) cohort. Lancet. 2024 Mar 30;403(10433):1279-1289.
4. Masoud S, Wong K, Downward L, Pitcher D, Webb NJ, Proudfoot C, RaDaR Consortium, Wong EK, Gale DP. Clinical Predictors of Long-term Outcomes in C3 Glomerulopathy and Immune-Complex Membranoproliferative Glomerulonephritis within the UK RaDaR Registry. medRxiv. 2024:2024-02.
Danish Multiple Sclerosis Registry (Denmark)
Database Contact Data
Melinda Magyari, MD, PhD
Associate Professor
Danish Multiple Sclerosis Center
Copenhagen University Hospital
Rigshospitalet Glostrup
Valdemar Hansens Vej 2, Entrance 8, Second floor
DK-2600 Glostrup
DENMARK
Email: melinda.magyari.01@regionh.dk
Cell: + 45 21 68 98 25
Alternate Contact
Jenni Dalsgaard
Research Administrator
The Danish Multiple Sclerosis Registry
Department of Neurology
Rigshospitalet Glostrup
Valdemar Hansens Vej 2, Entrance 8, Second floor
DK-2600 Glostrup
DENMARK
E-mail 1: jenni.lilian.dalsgaard@regionh.dk
Email 2: scleroseregisteret.rigshospitalet@regionh.dk
Phone: +45 3863 2750
References of Studies Using/Describing Database
1. Magyari M, Koechlin A, Duclos A, Kopp TI, Allaoui EM, Polazzi S, Seeldrayers P, Autier P. Long-Term Safety of Teriflunomide in Multiple Sclerosis Patients: Results of Prospective Comparative Studies in Three European Countries. Pharmacoepidemiol Drug Saf. 2024 Jul;33(7):e5866.
2. Mahler MR, Magyari M, Pontieri L, Elberling F, Holm RP, Weglewski A, Poulsen MB, Storr LK, Bekyarov PA, Illes Z, Kant M, Sejbaek T, Stilund ML, Rasmussen PV, Brask M, Urbonaviciute I, Sellebjerg F. Prognostic factors for disease activity in newly diagnosed teriflunomide-treated patients with multiple sclerosis: a nationwide Danish study. J Neurol Neurosurg Psychiatry. 2024 Apr 3:jnnp-2023-333265. doi: 10.1136/jnnp-2023-333265. Epub ahead of print. PMID: 38569873.
3. Papp V, Magyari M, Möller S, Sellebjerg F, Battistini JL, Svendsen KB, Søndergaard HB, Nilsson AC, Illes Z. Mortality of the Danish Nationwide AQP4 Antibody-Seropositive Neuromyelitis Optica Spectrum Disorder Patient Cohort. Neurology. 2024 Mar 12;102(5):e209147.
4. Framke E, Jennum PJ, Thygesen LC, Magyari M. Sleep disorders and sleep disturbances in persons with multiple sclerosis: A population-based matched case-control study in Denmark. Neuroepidemiology. 2024 Mar 21. doi: 10.1159/000538307. Epub ahead of print. PMID: 38513627.
5. Framke E, Thygesen LC, Malmborg M, Schou M, Sellebjerg F, Magyari M. Risk of cardiovascular disease in patients with multiple sclerosis treated with fingolimod compared to natalizumab: A nationwide cohort study of 2095 patients in Denmark. Mult Scler. 2024 Feb;30(2):184-191.
6. Koch-Henriksen NI, Thygesen LC, Sørensen PS, Magyari M. Using instrumental variables to correct for bias in real-world cohort studies of the effects of disease-modifying treatment in MS. Mult Scler. 2024 Jan;30(1):113-120.
7. Holm RP, Wandall-Holm MF, Sellebjerg F, Magyari M. Comorbidity in the aging population with multiple sclerosis: a Danish nationwide study. Front Neurol. 2023 Nov 24;14:1297709.
8. Butzkueven H, Hillert J, Soilu-Hänninen M, Ziemssen T, Kuhle J, Wergeland S, Magyari M, Berger JR, Moore N, Aydemir A, Bezemer I, Sabidó M. The CLARION study: first report on safety findings in patients newly initiating treatment with cladribine tablets or fingolimod for multiple sclerosis. Curr Med Res Opin. 2023 Oct;39(10):1367-1374.
9. Kontaxis S, Laporta E, Garcia E, Martinis M, Leocani L, Roselli L, Buron MD, Guerrero AI, Zabala A, Cummins N, Vairavan S, Hotopf M, Dobson RJB, Narayan VA, La Porta ML, Costa GD, Magyari M, Sørensen PS, Nos C, Bailon R, Comi G, On Behalf Of The Radar-Cns Consortium. Automatic Assessment of the 2-Minute Walk Distance for Remote Monitoring of People with Multiple Sclerosis. Sensors (Basel). 2023 Jun 29;23(13):6017.
10. Wandall-Holm MF, Holm RP, Pontieri L, Sellebjerg F, Magyari M. Socioeconomic status of the elderly MS population compared to the general population: a nationwide Danish matched cross-sectional study. Front Neurol. 2023 Jun 13;14:1214897.
Sep 17, 2024: Tutorial Update – How to conduct searches on B.R.I.D.G.E. TO DATA®
Our tutorial “How to Conduct a Search” has been updated to include our latest enhancements, to better serve pharmaceutical companies, database consultants, epidemiologists, and public health professionals. This tutorial offers an improved guide on the basics of searching for database profiles using keywords and/or defined criteria and explains how to save individual searches for future reference.
Sep 11, 2024: New Parkinson’s disease registry added
Started in 2015, the goal of the Utah Parkinson’s Disease Registry is to develop a database of accurate historical and current information for research and public health purposes. The collection of patient data is important for detecting disease incidence, and possible risk factors of PD and other related movement disorders.
Sep 10, 2024: New prescription registry from Denmark added
Starting in 2003, the Danish National Prescription Registry includes individual-level data on prescriptions filled by Danish residents at community pharmacies. The Danish community pharmacy sector consists of 314 large pharmacies, on average covering about 17,000 residents and serving about 600 customers per day. Data are received from records in the electronic dispensing systems of community pharmacies. The Registry contains 46 variables that characterize each redeemed prescription.